A Phase 1 Dose-Escalation and Phase 2 Randomized, Open-Label Study of Nivolumab and Veliparib in Combination With Platinum Doublet Chemotherapy in Subjects With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I/II
Latest Information Update: 24 Sep 2017
At a glance
- Drugs Nivolumab (Primary) ; Veliparib (Primary) ; Carboplatin; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
- 20 Sep 2017 This trial has been discontinued in Hungary.
- 06 Sep 2017 This trial has been discontinued in Czech Republic (end date: 2017-08-24)
- 17 Jul 2017 Planned End Date changed from 1 Jul 2021 to 23 Jun 2018.